Leber Hereditary Optic Neuropathy Clinical Trial
Official title:
Efficacy and Safety of Bilateral Intravitreal Injection of GS010: A Randomized, Double-Masked, Placebo-Controlled Trial in Subjects Affected With G11778A ND4 Leber Hereditary Optic Neuropathy for Up to One Year
The goal of this clinical trial is to assess the safety and efficacy of GS010, a gene therapy, in improving the retina functional & structural outcomes in subjects with LHON due to the G11778A ND4 mitochondrial mutation when vision loss duration is present up to one year.
GS-LHON-CLIN-05 is a Phase III, global, multi-center randomized, double-masked for the primary analysis, placebo-controlled, clinical study. As LHON is a neurodegenerative disease, the goal is to administer GS010 as soon as possible upon confirmation of the LHON diagnosis and the causative mutation. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03475173 -
New Non-invasive Modalities for Assessing Retinal Structure and Function
|
N/A | |
| Recruiting |
NCT02176733 -
Trial of Cyclosporine in the Acute Phase of Leber Hereditary Optic Neuropathy
|
Phase 2 | |
| Completed |
NCT03406104 -
RESCUE and REVERSE Long-term Follow-up
|
Phase 3 | |
| Completed |
NCT03295071 -
REALITY LHON Registry
|
||
| Recruiting |
NCT03011541 -
Stem Cell Ophthalmology Treatment Study II
|
N/A | |
| Completed |
NCT02064569 -
Safety Evaluation of Gene Therapy in Leber Hereditary Optic Neuropathy (LHON) Patients
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03153293 -
A Single Intravitreal Injection of rAAV2-ND4 for the Treatment of Leber's Hereditary Optic Neuropathy
|
Phase 2/Phase 3 | |
| Completed |
NCT01267422 -
Safety and Efficacy Study of rAAV2-ND4 Treatment of Leber Hereditary Optic Neuropathy (LHON)
|
N/A |